tski-vi and Vaccinia

The effect of the compound N,N'-bis/methylisatin-beta-thiosemicarbazone/-2-methylpiperazine (bis-MIBTP) on immune response in BALB/c and Swiss mice have been studied in the course of vaccinia virus infection. Humoral response tested by neutralization and hemagglutination inhibiting antibodies was similar in compound-treated mice to this of untreated mice. Cell-mediated immune response, examined by spleen lymphocytes migration inhibition test, has been delayed or temporally depressed in bis-MIBTP treated mice as compared with the control group. High protective activity of the compound in vaccinia infected mice in spite of impairment of cellular immunity may indicate that antibodies have played an important role in recovery process from vaccinia infection.

Topics: Animals; Antibodies, Viral; Antibody Formation; Binding, Competitive; Cell Movement; Female; Hemagglutination; Histocompatibility Antigens Class II; Lymphocytes; Male; Methisazone; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Neutralization Tests; Spleen; Thiosemicarbazones; Vaccinia

In this paper ectodermal lesions on the tails of mice inoculated intravenously with vaccinia virus were used to study the influence of N,N'-bis[methylisatin-beta-thiosemicarbazone]-2-methylpiperazine (TSKI VI) on the number and dynamics of lesion formations. The activity of this compound was compared to that of the antiviral drug, methisazone. The reduction in lesions after treatment with TSKI VI was similar to the reduction induced by methisazone, which, on the basis of earlier theroretical and experimental data as well as on the lower toxicity of TSKI VI for the tissues and a more favorable therapeutic index, makes this compound worth considering in the treatment of postvaccinal complications. This method proved very useful in examination of the substances having potential prophylactic properties in preventing generalized infections.

Topics: Animals; Antiviral Agents; Methisazone; Mice; Piperazines; Skin; Thiosemicarbazones; Vaccinia

N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine (TSKI-VI) proved to be significantly effective against lethal vaccinia, pseudorabies and Mengo virus-induced encephalitis in different strains of mice when administered subcutaneously (s.c.) in doses of 20 mg/kg body weight, twice daily, for a period of five days. The strongest effects occurred in vaccinia virus-infected mice, and the degree of protection was both dose- and virus-dependent. Titres of vaccinia virus in brains of infected mice were slightly lower in TSKI-VI or methisazone-treated mice as compared to virus controls.

Topics: Animals; Dose-Response Relationship, Drug; Encephalitis; Enterovirus Infections; Female; Male; Mengovirus; Methisazone; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Piperazines; Pseudorabies; Thiosemicarbazones; Vaccinia

The inhibitory effect of N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine (compound TSKI-VI) and methisazone (Marboran) on the growth of vaccinia virus (IHD strain) was studied in vitro and in vivo. The therapeutic indices of both compounds determined in vivo were similar, but TSKI-VI was found more efficient in vitro.

Topics: Animals; Chemical Phenomena; Chemistry; Chick Embryo; Culture Techniques; Female; Fibroblasts; Male; Methisazone; Mice; Piperazines; Thiosemicarbazones; Vaccinia; Vaccinia virus; Virus Replication